Drug Origin Transparency Act of 2026

This bill changes federal drug law to require more detailed reporting on where drugs and their ingredients come from. Companies that report drug manufacturing amounts to the Food and Drug Administration would have to include supplier details for active ingredients and in-process materials, as specified by the Secretary, and the amounts made using each supplier's materials. Reports would be due more often than once a year, but no more than four times a year. Drug labels, including labels on active pharmaceutical ingredients, would have to show the name, place of business, and facility identifier of the original manufacturer, and drug labeling would have to list the original manufacturer of each active ingredient, any other manufacturer, and the packer or distributor.

Full text and official record on Congress.gov

Sponsors

• Doris O. Matsui Democrat sponsor
• 3 cosponsors